Bradda HeadāÆ Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah I think it has a way to go yet, bought back in here
This share is flying. I had set 6p as my sell price but Iām going to stay in longer and hope it continues to head towards. Maybe 10p target.
Thanks for the ride AGY, good luck!
Ha putting through large sells then cancelling. No stock
5p š„³ party on my own.
Interesting movement on L2 :)
15p. Will be bought out.
Anyone got any idea what sort of value this company could reach if everything comes together? What are people's sp target?
Immediate focus will be preparing the data package for national MAA in Q4 alongside exploration for potential collaborations for US expansion.
Cannot buy a bean
GLA
Also got the peanut trials, market is huge there.
Agreed. Q4 seems like a long way off but will soon come round. Would be nice to see a sp bounce today.
Company is going places
ROFL looked at those delayed trades (buys) from yesterday. Baaaah
Finally, Prof. Shamji will host an embargo session at the closure day of the EAACI conference to release the Group's recently accepted VLP Peanut paper in the peer reviewed Journal of Allergy and Clinical Immunology, the official publication of the American Academy of Allergy, Asthma, and Immunology (AAAAI). This session will highlight the promising biomarker safety and efficacy profile of VLP Peanut, including the first clinical results supporting the hypo-allergic profile of VLP Peanut based on the skin test results from the PROTECT Phase I/IIa study.
Presuming news Monday?
Extremely low float, trending north this will make serious moves on next news if positive. Presumably they want to get the price up quite a bit above the warrants and add some liquidity.
Ride that wave.
But I managed with a little patience to add 25k shares just now at 4.17p
GLA
Been some decent buying here last two sessions
I think anything in the Biotech space will do well at the moment. Expect to see AI profits moving towards it, synthetic biotechs is the space to be (I know they are not that) but expect to see pharma sector do well.
Trending up, extremely small float and funding sorted. Did not realise how big the peanut allergy market was.
As per RNS 7th May
Allergy Therapeutics provides further detail from positive top line results from G306 Phase III field trial to evaluate efficacy and safety of Grass MATA MPL
As previously communicated, the treatment was well tolerated with no unexpected safety signals. Further exploratory endpoint analyses (including an extensive biomarker evaluation) of the G306 trial are now underway. Full results, including secondary and exploratory endpoints, will be presented at the upcoming European Academy of Allergy & Clinical Immunology conference in June 2024 and submitted for peer-reviewed publication later this year. The Group's preparation for the marketing authorisation application (MAA) is well underway, with a planned submission in Q4 2024
Took a position today.
Patiently waiting for goods news, this will move very quickly soon.
WHERE TF is everyone??? ššš
Agree, moving in the right direction, was hoping for some small movement today.
This is under the radar at the moment, I do think it will suddenly have a large jump once we get more updates on the treatment trials. Could then be bought out by a large company for millions
Annnnd no comments? Wakey, wakey folks.
Good news imo but welcome your comments.